33 results about "Oncocyte" patented technology

The invention discloses a method for detecting the assembly change of an ASGPR (asialoglycoprotein receptor) on the surface of a hepatocyte, which comprises the following steps: carrying out specific labeling on the ASGPR on the surface of the hepatocyte through an antibody, and carrying out fluorescence imaging on the ASGPR on the surface of a cell membrane, the purpose of detecting ASGPR assembly change on the liver cell membrane is achieved by statistically analyzing the number of ASGPR protein positioning points on the surface of the cell membrane and aggregation parameters. According to the method, the distribution and aggregation condition of the ASGPR on the cell surface is measured through the nanoscale resolution, the change of the ASGPR in the cell membrane assembly relation is detected, damage to sample cells is small, the time cost of the experimental process is small, protein positioning is accurate, and as the ASGPR is an endocytosis receptor specifically existing on the surface of hepatocellular carcinoma cells, the detection result is accurate, and the detection accuracy is high. Efficient treatment can be achieved through a drug delivery system formed by targeting ASGPR, ASGPR can be better known by observing the assembly difference of ASGPR on the surface of a cell membrane from the nanoscale, and the method has wide application prospects in the field of medical detection and diagnosis.

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof. The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The present invention relates to an N-containing heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. The derivative exhibits high inhibitory activity against various protein kinases, particularly excellent ret proto-oncogene (RET) enzyme inhibitory ability, and has an excellent effect of inhibiting the proliferation of medullary thyroid cancer cells and lung cancer cells, which express RET fusion genes, and thus the derivative can be effectively used in the treatment of cancer, for example, medullary thyroid cancer or lung cancer, and particularly, can be effectively used in the treatment of cancer in which RET fusion genes are expressed.

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

Provided are methods of treating cancer in a patient in need thereof, the cancer co-expressing one or more placental alkaline phosphatase (ALPP) proteins, and a cancer target antigen, comprising administering to the patient a treatment regimen, wherein the therapeutic regimen comprises administering one or more standard care inhibitors or anti-proliferative agents that increase cell surface expression of the one or more ALPP proteins, and one or more ALPP protein targeting agents. Also provided are methods of selecting a patient suffering from a cancer co-expressing one or more placental alkaline phosphatase (ALPP) proteins, and a cancer target antigen, comprising: determining a baseline cell surface expression level of the one or more ALPP proteins in a biological sample obtained from the patient; and determining co-expression of one or more cancer cell surface oncogenic drivers.

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by β-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof.The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The invention relates to application of theaflavin as a UGP2 inhibitor and application of theaflavin in preparation of a medicine for preventing and / or treating hepatocellular carcinoma, and belongs to the technical field of biology. According to the invention, the monomeric compound theaflavin derived from a natural product can be used as a UGP2 direct targeting inhibitor for the first time, and is used for preparing a liver cancer treatment medicine for regulating and controlling glucose metabolism reprogramming. The theaflavin can be specifically and directly combined at a UGP2 active site in a targeting manner through high activity to inhibit the activity of the UGP2, is the first specific inhibitor which takes the UGP2 as a target spot and is reported at present, and can be used for remarkably inhibiting tumor phenotypes such as proliferation, migration and invasion of liver cancer cells by inhibiting UGP2-mediated UDPG synthesis and intracellular glycogen accumulation.

The invention relates to a glutathione probe, a preparation method and application thereof, and a bifunctional glutathione probe, which consumes bimolecular glutathione through a sequential activation strategy, so that high fluorescence enhancement is realized, and the accuracy of glutathione response imaging is realized. The Cy-ResNPs shows selective accumulation in mitochondria, the level of reactive oxygen species (ROS) is effectively improved by consuming glutathione, including induction of superoxide anions, and efficient photodynamic therapy is achieved. Intracellular oxidative stress storms induced by a variety of pathways promote iron apoptosis, cell apoptosis, and lethal toxicity in cancer cells. Finally, the Cy-ResNPs realizes accurate diagnosis and effective treatment in transplantable and rapid proliferative melanoma tumors. The research has important significance for tumor therapeutic research by consuming the intelligent small molecular fluorescent agent of glutathione in the future.

The present invention relates to gene editing agents (e.g., CRISPR / Cas) that target mutated oncogenes (e.g., a mutated oncogene a cancer is addicted to) and uses thereof (e.g., for inactivation of mutated oncogenes and / or treatment cancer). In some embodiments, the mutated oncogene is a mutated KRAS. In some embodiments, the cancer is pancreatic ductal adenocarcinoma, non-small cell lung cell, or colorectal cancer.

The invention belongs to the technical field of biological medicine, and discloses application of a CRM1-PROM2 signal axis inhibitor in preparation of a gastric cancer cell ferroptosis inducer sensitizer, an anti-gastric cancer drug and a predictive marker. In the application provided by the invention, the CRM1-PROM2 signal axis is destroyed or inhibited by the CRM1-PROM2 signal axis inhibitor, so that the level of PROM2 in gastric cancer cytoplasm can be reduced, and then downstream KEAP1 / NRF2, FPN iron ion efflux and other ferroptosis resistance related signal axes are interfered, so that the ferroptosis sensitivity of gastric cancer cells is improved, and the treatment effect of the ferroptosis inducer on gastric cancer is enhanced; and the inhibitor shows certain targeting property in the aspect of enhancing the treatment effect of the ferroptosis inducer on the gastric cancer, and has important significance in realizing accurate diagnosis and treatment of the gastric cancer.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a 1, 2, 4-triazole compound as well as a preparation method and application thereof. The 1, 2, 4-triazole compound provided by the invention has a structure as shown in a formula I: # imgabs0 # test results show that the 1, 2, 4-triazole compound provided by the invention not only has a better selective inhibition effect on HDAC6 protein, but also can inhibit proliferation of gastric adenocarcinoma cells, has a protection effect on myocardial cells, and can be used for preparing a medicine for treating gastric adenocarcinoma cells. The compound can be developed and applied as an HDAC6 inhibitor, an anti-gastric cancer drug or a myocardial protection drug. Therefore, the skeleton type of the compound in an HDAC6 inhibitor is enriched, and meanwhile, a new direction and data support are provided for developing an anti-tumor drug which is low in myocardial injury risk and has HDAC6 selectivity.

The present disclosure provides compounds of formula (I′) and uses thereof for the treatment of cancer. Also provided are pharmaceutical compositions and kits comprising the same compounds. The present compounds may have improved anti-tumor effect and reduced toxicity and may be useful for targeting mitochondria in cancer cells.

The invention discloses application of a reagent for detecting or inhibiting a TCF7L2-Exon14 shear isomer and an oral cancer treatment medicine, and belongs to the technical field of tumor molecular biology. According to the invention, the expression condition of the TCF7L2-Exon14 shear isomer is detected in normal oral mucosa epithelial cells and oral cancer cells by using a semi-quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) technology. The result shows that compared with normal oral mucosa epithelial cells, the expression of the TCF7L2-Exon14 shear isomer in oral cancer tissues is obviously improved. Therefore, the TCF7L2-Exon14 shear isomer is highly expressed in oral cancer tissues, possibly has an important biological function for occurrence and development of oral cancer, and can be used as an oral cancer diagnosis molecular marker and a treatment target.

The invention belongs to the technical field of medical biology, and particularly relates to application of IGFBP7 in preparation of a medicine for treating gastric adenocarcinoma. IGFBP7 closely related to gastric adenocarcinoma is screened out as a molecular marker through multiple bioinformatics technologies, expression of IGFBP7 in gastric adenocarcinoma is detected through immunohistochemistry, and prognosis of a patient is evaluated by establishing a scoring system combining dyeing intensity and positive cell proportion. Experimental results show that IGFBP7 knock-down can effectively inhibit proliferation and migration of gastric adenocarcinoma cells, induce apoptosis and trigger S-phase arrest. Furthermore, a co-culture experiment of gastric adenocarcinoma cells and mononuclear cells reveals that IGFBP7 can promote polarization of M2 type macrophages in a gastric adenocarcinoma tumor immune microenvironment.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as pharmaceutical agents, particularly for the treatment of proliferative, inflammatory, and / or genetic disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I). Furthermore, the present invention relates to methods for inhibiting the growth, proliferation, or metastasis of cancer cells in a subject in need thereof, which may include, in particular, a subset of patients defined by their RAS oncogene mutation status, or patients who have developed resistance to standard treatment or treatment with RAS mutation-specific inhibitors. The present invention also relates to methods for inhibiting RAS molecules in the treatment of genetic disorders such as RAS syndromes or inflammatory diseases such as adenomyosis in which the KRAS gene is activated by mutations. The present invention also relates to methods for inhibiting the proliferation and / or secretion of factors from cell populations sensitive to in vitro inhibition of RAS activation, particularly cell populations sensitive to in vitro inhibition of KRAS, HRAS, and NRAS activation. Furthermore, the present invention relates to kits containing formulations of pharmaceutical compositions containing compounds of formula (I).

Chimeric viruses having a vesicular stomatitis virus (VSV) background where the VSV G protein is supplemented or replaced with an alphavirus glycoprotein(s), or a functional fragment(s) thereof, are provided. A preferred alphavirus is Chikungunya virus. In particular embodiments, the glycoprotein(s) is or includes E3, E2, K6, and E1 proteins of an alphavirus, preferably Chikungunya virus. Methods of using the chimeric viruses for treatment of cancers, particularly brain cancers and metastasis thereof are also provided. In some embodiments, the chimeric viruses retain superior oncolytic activity to infect and destroy cancer cells selectively, such as glioblastoma and intracranial melanoma metastases. In some embodiments, the chimeric viruses have reduced toxicity to e.g., heathy cells relative to a control such as the parent VSV with the VSV G protein.

The invention provides an application of Mito-apocynin in preparation of a medicine for treating liver cancer. It is found for the first time that Mito-apocynin has remarkable anti-hepatoma activity, oxidative stress is induced to generate a large amount of reactive oxygen species (ROS) to trigger oxidative stress by targeting mitochondria, namely a cell energy factory and an apoptosis control center, high-level ROS induces hepatoma cell apoptosis, proliferation of hepatoma cells is effectively inhibited, and therefore hepatoma cells are effectively killed.

A pharmaceutical composition includes: (a) a targeting agent for cancer cell mitochondria, (b) an ion chelating agent, and (c) pharmacologically active multivalent ions. The weight ratio of (a) is 64.5%˜43.7% based on the total weight of the pharmaceutical composition, the weight ratio of (b) is 56.2%˜16.1% based on the total weight of the pharmaceutical composition; the weight ratio of (c) is 19.4%˜0.000116% based on the total weight of the pharmaceutical composition.

The invention discloses application of shPPIA in preparation of a molecular targeted therapeutic drug for inhibiting gastric cancer progression, and relates to the technical field of biomedicine.The drug inhibits gastric cancer cell proliferation by down-regulating the expression level of shPPIA, and the drug inhibits eEF1A1 protein stability by inhibiting PPIA expression, reduces nuclear translocation of eEF1A1 protein, inhibits eEF1A1-MDM2 interaction and up-regulates p53 protein expression by down-regulating eEF1A1 protein stability by down-regulating eEF1A1 protein stability by down-regulating eEF1A1 protein nuclear translocation by down-regulating eEF1A1 protein expression by down-regulating eEF1A1 protein expression; the medicine is used for inhibiting proliferation, migration or invasion of gastric cancer cells and / or promoting apoptosis of the gastric cancer cells. According to the application, shPPIA is provided through in-vitro and in-vivo experiments to serve as evidence of a new therapeutic target, a cancer promoting mechanism of a PPIA-eEF1A1-MDM2-p53 signal axis is disclosed, the problem that an existing targeted drug is insufficient in curative effect is solved through the provided composition, proliferation and metastasis of gastric cancer cells can be effectively inhibited, and a new clinical transformation strategy is provided for gene therapy of gastric cancer.

The invention relates to lactobacillus reuteri LR35 beneficial to female genital tract health and having the function of improving gastritis and application of the lactobacillus reuteri LR35. The LR35 strain has excellent acid resistance, acid production capacity, self-agglutination capacity and vaginal epithelial cell adhesion capacity; common vaginal pathogenic bacteria can be antagonized; adhesion and reproduction of pathogenic bacteria can be prevented, and a competitive repulsive effect is achieved; the composition also has an excellent effect of inhibiting inflammatory factors; the symptoms of a mixed vaginitis mouse model can be improved. Meanwhile, the strain also has an antagonistic effect on the main pathogenic bacterium helicobacter pylori causing gastritis, and can form a copolymer with the helicobacter pylori to discharge the helicobacter pylori out of a body; and the traditional Chinese medicine composition also has an inhibiting effect on inflammatory factors secreted by human gastric adenocarcinoma cells, namely has a good potential of improving inflammatory response caused by helicobacter pylori.

A composition, comprising at least two of: (a) a targeting agent for cancer cell mitochondria, (b) an ion chelating agent, and (c) a multivalent ion having pharmacological activity, wherein the weight ratio of (a) is 22.0%-98.4% on the basis of the total weight of the composition, the weight ratio of (b) is 37.9%-98.8% on the basis of the total weight of the composition, and the weight ratio of (c) is 0.69%-64.5% on the basis of the total weight of the composition; and the use thereof.

The present invention provides novel mito-pyridinium compounds, prodrugs and the uses thereof for the treatment of cancer, particularly drug resistant cancer.

To provide novel therapeutic compounds that target and inhibit a mitochondrial function, and may serve as anti-cancer therapeutics.SOLUTION: Alkyl-triphenylphosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the bulk of the adherent of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently inhibits a mitochondrial oxygen consumption rate, while simultaneously shifting cell metabolism toward a glycolytic pathway. This shift to a strict metabolic dependency on glycolysis may be used to eradicate the residual glycolytic CSC population, by using additional metabolic stressors. For example, d-TPP may be combined with a glycolytic inhibitor or an OXPHOS inhibitor, through co-administration or sequential administration, to treat cancer and eradicate CSCs.SELECTED DRAWING: Figure 2

In the present invention, the role of indoxyl sulfate (IS) has been investigated for its selective anti-cancer activity on colon cancer cells. IS treatment to HCT-116 and HT-29 human epithelial adenocarcinoma cells led to a decrease in cell proliferation, cell viability and ATP content. Colon cancer cells showed a 10% increase in cell apoptosis in comparison to a control. Due to IS treatment, cell morphology was distorted, cell number found decreased, intracellular vesicles formed, and cells were found floated in the media. Cells also showed loss in membrane integrity and decrease in colony forming ability and ceased at G2 / M phase of cell cycle. No significant change was noted in the level of inflammatory cytokines IL-17A, IL-1β and TNF-α, histology, length of intestine and spleen, after 100 mM IS treatment to balb / c mice. These observations indicate selective anticancer effect of IS to colon cancer cells.

The invention belongs to the technical field of organic synthesis, and provides a mitochondrial targeting and viscosity-sensitive near-infrared fluorescent probe as well as a preparation method and application thereof. The fluorescent probe has positive charges, can be selectively enriched in mitochondria, and can dynamically monitor the viscosity of the mitochondria. The synthesis steps of the probe are short, and post-treatment is easy; the selectivity, the sensitivity and the stability are high. The excitation wavelength and the emission wavelength are in a near-infrared region, so that biological autofluorescence interference can be effectively avoided, and deep tissue penetration potential is achieved. The probe has been successfully applied to real-time monitoring of mitochondrial viscosity level in cancer cell autophagy and apoptosis processes and detection of viscosity change in zebrafish under nystatin stimulation. The invention provides an efficient tool for dynamic monitoring of mitochondrial viscosity, has important application value in the aspects of early diagnosis, efficacy evaluation and the like of mitochondrial related diseases such as cancer and the like, and meets clinical and scientific research requirements.

The invention discloses a preparation method and application of a coumarin-modified mitochondria-targeted fluorescent semi-sandwich structure iridium and ruthenium complex. The structural formula of the complex is as shown in formula (I). By introducing a coumarin group, the complex is endowed with fluorescence characteristics, and the complex can target mitochondria, has good anti-cancer activity and tracing function, can be selectively accumulated in cancer cell mitochondria to induce apoptosis, and can be used for preparing a fluorescent probe by virtue of the self-luminescence property. Researchers are helped to track intracellular transport distribution of drugs in real time, interaction between the drugs and biological target molecules is monitored, and an important research means is provided for revealing drug action mechanisms and targets. The preparation method disclosed by the invention is high in synthesis efficiency, and the prepared target complex has imaging capability and anti-cancer characteristic at the same time and is expected to become a novel multifunctional diagnosis and treatment reagent.

The present invention relates to the use of Megasphaera bacteria in the preparation of drugs for treating cancer, belonging to the field of biomedicine technology. The present invention provides the use of Megasphaera bacteria XA-511 in the preparation of drugs for preventing and / or treating cancer. XA-511 can cooperate with anti-PD-1 antibodies to reduce the number and volume of tumors in mice with orthotopic colorectal cancer models, inhibit the formation of tumors in mice with orthotopic colorectal cancer models, and can cooperate with anti-PD-1 antibodies to enhance the expression of CD8 + T and CD4 + XA-511 can synergize with anti-PD-1 antibodies to reduce tumor weight and volume in pancreatic cancer model mice, and can synergize with anti-PD-1 antibodies to reduce CD4 + T infiltration, and can cooperate with anti-PD-1 antibodies to increase CD8 + Infiltration of T.